OncoSil Medical Ltd’s (ASX:OSL) pancreatic cancer clinical study has demonstrated significant local disease control with up to 73% reduction in tumour volume observed 4 weeks post implant.
The company’s lead product, OncoSil™, is a targeted radioactive isotope, implanted directly into a patient’s pancreatic tumour via an endoscopic ultrasound.
Treatment with OncoSil is intended to deliver more concentrated and localised beta radiation compared to external beam radiation.
OncoSil has provided an overview of early study results at the European Association of Nuclear Medicine (EANM) Congress, which took place in Vienna on 21 October 2017.
Positive data from the first group of patients who completed CT imaging in the 8, 16 and 24-week study follow-up periods was presented by OncoSil.
This early study data is consistent with previously completed studies that validated the safety, efficacy and delivery of the OncoSil™ device.
OncoSil continues to progress patient recruitment of its global pancreatic cancer clinical study program, with 28 subjects now enrolled into the study group.
The company will continue to recruit subjects beyond the initial 20 subject target to gather additional valuable clinical experience and to account for subject loss due to factors such as withdrawal.
It is worth noting that the prognosis for patients diagnosed with pancreatic cancer, regardless of stage, is generally poor; the relative five-year survival rate for all stages combined is circa 5%.
The estimated worldwide market opportunity for OncoSil in pancreatic cancer exceeds $1 billion.
